# C1-Esteraseremmer-N for the Treatment of Hereditary (and Acquired) Angioedema

> **NCT00125541** · PHASE2,PHASE3 · COMPLETED · sponsor: **Prothya Biosolutions** · enrollment: 6 (estimated)

## Conditions studied

- Angioedema

## Interventions

- **DRUG:** C1 inhibitor concentrate (C1-esteraseremmer-N)

## Key facts

- **NCT ID:** NCT00125541
- **Lead sponsor:** Prothya Biosolutions
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2006-11
- **Primary completion:** 2008-04
- **Final completion:** 2008-05
- **Target enrollment:** 6 (ESTIMATED)
- **Last updated:** 2009-05-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00125541

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00125541, "C1-Esteraseremmer-N for the Treatment of Hereditary (and Acquired) Angioedema". Retrieved via AI Analytics 2026-07-20 from https://api.ai-analytics.org/clinical/NCT00125541. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*